A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer
Kaufman D, Carducci M, Kuzel T, Todd M, Oh W, Smith M, Ye Z, Nicol S, Stadler W. A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urologic Oncology Seminars And Original Investigations 2004, 22: 393-397. PMID: 15464919, DOI: 10.1016/j.urolonc.2004.01.002.Peer-Reviewed Original ResearchConceptsMetastatic urothelial cancerUrothelial cancerResponse rateMulti-institutional phase II trialPhase II trial of gemcitabineTrial of gemcitabineAdequate organ functionWorld Health OrganizationPoor renal functionOverall response ratePartial responseCombined gemcitabineMedian survivalPrognostic groupsInsufficiency patientsPerformance statusRenal functionTherapy statusGrade 3Treated patientsBiweekly schedulePatientsRoutine useOrgan functionGemcitabine
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply